US EditionParadigm to seek FDA approval for epidermolysis bullosa treatment
Summary by Epidermolysis Bullosa News
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Paradigm to seek FDA approval for epidermolysis bullosa treatment
Paradigm Therapeutics is planning to seek U.S. Food and Drug Administration (FDA) approval for the experimental cream SD-101 to treat all forms of epidermolysis bullosa (EB). Paradigm said it plans to submit a new drug application in the latter part of this year. If SD-101 ultimately is approved, Paradigm plans to sell it under the name Zorblisa. “We are excited about the opportunity to complete the development activities for SD-101 (Zorblisa) a…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
